Worldwide Webinar Series:

Impact of Modeling & Simulation in Drug Development

Rosa’s Worldwide Webinar Series fosters the adoption of modeling and simulation by informing a broad audience about the strategic impact it can have on all aspects of research and development.

Since its inception in 2011, this complimentary monthly series has featured select speakers from academia, industry, Rosa client companies, and Rosa itself. The series has drawn many thousands of attendees worldwide from all drug development disciplines.

PLEASE NOTE - ***ALL WEBINARS PRIOR to 2017*** are available by contacting us CLICK HERE

Sign up to receive Webinar and QSP News Alerts

Date	Presenter / Topic	Register
Feb 12, 2025 09:00 AM - 10:00 AM PACIFIC TIME	David Turner, PhD, Distinguished Scientist David Turner is currently a Distinguished Scientist in the Department of Clinical Pharmacology at Genentech, since September 2021. He has over ten years of experience in Clinical Pharmacology and Modeling and Simulation, contributing to various global regulatory submissions and health authority interactions. At Merck, he was part of the Clinical Pharmacology team working on pembrolizumab approvals in melanoma and metastatic NSCLC, which has since become a standard of care in these settings. Before joining Genentech, David worked at GSK as a clinical pharmacology lead for oncology programs, where he helped develop MBMA methods to compare internal and external oncology treatments. At Genentech, he is involved as a Clin Pharm lead with the mosunetuzumab (bispecific anti-CD20/CD3) program, assisting in its initial regulatory submissions and approvals for relapsed/refractory follicular lymphoma. David has authored over 40 publications, delivered four oral presentations, and presented more than 20 conference posters. His research on exposure-response confounding has been recognized for its influence on the field and dose selection practice for biologic treatments. Joseph Chen, PharmD, Senior Principal Scientist Joseph Chen is a Senior Principal Scientist in the Genentech Clinical Pharmacology, Oncology group, supporting large molecule oncology drug development including atezolizumab (anti-PD-L1 mAb). Prior to joining Genentech, he worked as a clinical pharmacologist at Pfizer, supporting small molecule oncology drug development, including Lorbrena, an approved ALK-inhibitor small molecule TKI in NSCLC. He received his PharmD at the UCSD Skaggs School of Pharmacy in 2016. Russ Wada, Principal Consultant, QuanTx Consulting QuanTx Consulting is a QCP consulting services company with focus on pharmacometrics, located in Mountain View CA. Russ Wada is the Founder and a Principal Consultant at QuanTx Consulting. Previously Russ worked at Pharsight, Quantitative Solutions, and Certara. He has over 25 years of experience as a modeling and simulation consultant in drug development. He received his PhD in Engineering from UCLA and did a postdoctoral fellowship in Clinical Pharmacology in the Dept of Anesthesiology at Stanford. Leveraging Model-Based Meta-Analysis to Enhance Decision-Making in Metastatic NSCLC Treatment	More Info

Feb 12, 2025 09:00 AM - 10:00 AM PACIFIC TIME

David Turner, PhD, Distinguished Scientist
David Turner is currently a Distinguished Scientist in the Department of Clinical Pharmacology at Genentech, since September 2021. He has over ten years of experience in Clinical Pharmacology and Modeling and Simulation, contributing to various global regulatory submissions and health authority interactions. At Merck, he was part of the Clinical Pharmacology team working on pembrolizumab approvals in melanoma and metastatic NSCLC, which has since become a standard of care in these settings.

Before joining Genentech, David worked at GSK as a clinical pharmacology lead for oncology programs, where he helped develop MBMA methods to compare internal and external oncology treatments. At Genentech, he is involved as a Clin Pharm lead with the mosunetuzumab (bispecific anti-CD20/CD3) program, assisting in its initial regulatory submissions and approvals for relapsed/refractory follicular lymphoma.

David has authored over 40 publications, delivered four oral presentations, and presented more than 20 conference posters. His research on exposure-response confounding has been recognized for its influence on the field and dose selection practice for biologic treatments.

Joseph Chen, PharmD, Senior Principal Scientist
Joseph Chen is a Senior Principal Scientist in the Genentech Clinical Pharmacology, Oncology group, supporting large molecule oncology drug development including atezolizumab (anti-PD-L1 mAb). Prior to joining Genentech, he worked as a clinical pharmacologist at Pfizer, supporting small molecule oncology drug development, including Lorbrena, an approved ALK-inhibitor small molecule TKI in NSCLC. He received his PharmD at the UCSD Skaggs School of Pharmacy in 2016.
Russ Wada, Principal Consultant, QuanTx Consulting
QuanTx Consulting is a QCP consulting services company with focus on pharmacometrics, located in Mountain View CA. Russ Wada is the Founder and a Principal Consultant at QuanTx Consulting. Previously Russ worked at Pharsight, Quantitative Solutions, and Certara. He has over 25 years of experience as a modeling and simulation consultant in drug development. He received his PhD in Engineering from UCLA and did a postdoctoral fellowship in Clinical Pharmacology in the Dept of Anesthesiology at Stanford.

Leveraging Model-Based Meta-Analysis to Enhance Decision-Making in Metastatic NSCLC Treatment

More Info